WhaleCreep

Avidity Partners Management LP 13F holdings, Q3 2020

Hedge fundSEC filingsCompare with another fundHoldings as of 2020-09-30, filed 2020-11-16

Avidity Partners Management LP disclosed 66 US equity positions worth $1.9bn in its Q3 2020 13F filing. Its largest position is ABBV at 7.2% of the reported book, followed by SGENEUR and AVTR. Versus Q2 2020 it opened 43 new positions, added to 15, reduced 8 and exited 34.

$1.9bn
Reported equity book
Sum of the long US equity positions in the filing, at the values filed. Options are excluded.
66
Positions
Distinct securities in the equity book with a reported value above zero. Options are excluded.
7.2%
Largest position
The largest single position as a share of the reported equity book.
45.7%
Top 10 weight
The ten largest positions together, as a share of the reported equity book.
32
Effective positions
1 / HHI of portfolio weights: the number of equal-weight positions the book behaves like.
27
Quarters on file since Q4 2019
Quarters for which this manager's 13F holdings are on record.

Holdings

Against Q2 2020: 43 new, 15 added, 8 reduced, 34 exited

50 of 66
ABBV ABBVIE INCHealthcare7.2%$133m1.52m−1.5%reduced
SGENEUR SEATTLE GENETICS INC–5.6%$104m531,100+112%added
AVTR AVANTOR INCHealthcare5.5%$103m4.56m+183%added
MRK MERCK & CO. INCHealthcare5.1%$94.9m1.14m–new
BIIB BIOGEN INCHealthcare4.8%$89.4m315,100–new
BIOHAVEN PHARMACTL HLDG CO L no ticker–4.5%$83.5m1.28m+16%added
HORIZON THERAPEUTICS PUB L no ticker–3.9%$72.3m930,200+73%added
NBP NOVABRIDGE BIOSCIENCESHealthcare3.4%$63.0m1.34m–new
AUPH AURINIA PHARMACEUTICALS INCHealthcare2.8%$52.5m3.56m+44%added
TMO THERMO FISHER SCIENTIFIC INCHealthcare2.8%$52.2m118,300–new
BRISTOL-MYERS SQUIBB CO no ticker–2.7%$51.0m22.68m+292%added
BAX BAXTER INTL INCHealthcare2.7%$49.9m620,000−23%reduced
ELV ELEVANCE HEALTH INCHealthcare2.6%$47.4m176,400–new
DGX QUEST DIAGNOSTICS INCHealthcare2.5%$46.0m402,000–new
MRTXEUR MIRATI THERAPEUTICS INC–2.5%$45.7m275,000–new
QDELUSD QUIDEL CORP–2.1%$38.8m176,879–new
BSX BOSTON SCIENTIFIC CORPHealthcare2.0%$37.0m967,100–new
CHNGUSD CHANGE HEALTHCARE INC–2.0%$36.7m2.53m–new
NTRA NATERA INCHealthcare2.0%$36.4m503,400–new
KDMN KADMON HLDGS INC–1.9%$35.4m9.03m+41%added
ARVN ARVINAS INCHealthcare1.7%$31.8m1.35m+25%added
ZNTL ZENTALIS PHARMACEUTICALS INCHealthcare1.6%$29.6m904,119+34%added
SNDX SYNDAX PHARMACEUTICALS INCHealthcare1.5%$27.4m1.85m+21%added
CTLTEUR CATALENT INC–1.5%$27.2m318,100–new
IOVA IOVANCE BIOTHERAPEUTICS INCHealthcare1.4%$26.3m799,000+8.2%added
TREUR TRILLIUM THERAPEUTICS INC–1.3%$24.8m1.75m–new
BTAI BIOXCEL THERAPEUTICS INC–1.3%$23.3m538,000+39%added
HUM HUMANA INCHealthcare1.1%$21.3m51,500–new
ANIK ANIKA THERAPEUTICS INCHealthcare1.1%$21.3m601,700+66%added
COLL COLLEGIUM PHARMACEUTICAL INCHealthcare1.1%$20.8m1.00m–new
HARPOON THERAPEUTICS INC no ticker–1.1%$19.9m1.17m−2.9%reduced
AMARIN CORP PLC no ticker–1.0%$19.0m4.51m–new
ATHIRA PHARMA INC no ticker–1.0%$18.9m1.03m–new
MDT Medtronic PlcHealthcare1.0%$18.8m181,000+4.2%added
EXEL EXELIXIS INCHealthcare1.0%$18.8m769,200−71%reduced
APLSUSD APELLIS PHARMACEUTICALS INC–1.0%$18.8m623,300–new
AKBA AKEBIA THERAPEUTICS INCHealthcare1.0%$18.4m7.32m–new
ADAPY ADAPTIMMUNE THERAPEUTICS PLCHealthcare0.9%$16.6m2.08m+45%added
EPIEUR ESSA PHARMA INC–0.8%$14.4m2.09m–new
BNTX BIONTECH SEHealthcare0.8%$14.3m206,000–new
MERSANA THERAPEUTICS INC no ticker–0.8%$14.1m757,400−29%reduced
IDYA IDEAYA BIOSCIENCES INCHealthcare0.7%$13.2m1.05m−21%reduced
ZYME ZYMEWORKS INCHealthcare0.6%$11.4m244,700–new
ALDX ALDEYRA THERAPEUTICS INCHealthcare0.6%$10.6m1.43m–new
TSHA TAYSHA GENE THERAPIES INCHealthcare0.5%$8.8m392,000–new
DVAX DYNAVAX TECHNOLOGIES CORP–0.5%$8.7m2.02m−24%reduced
AXSM AXSOME THERAPEUTICS INC.Healthcare0.5%$8.4m118,000−71%reduced
2662247D ITEOS THERAPEUTICS INC–0.4%$8.1m330,000–new
ACIU AC IMMUNE SAHealthcare0.4%$7.6m1.55m–new
NVLSEUR ALPINE IMMUNE SCIENCES INC–0.4%$7.1m810,000–new

Exited since Q2 2020

34 rows
REGN REGENERON PHARMACEUTICALS5.3%$82.4m
IMMU IMMUNOMEDICS INC4.3%$67.7m
ALXN ALEXION PHARMACEUTICALS INC3.7%$57.0m
HO1 HOLOGIC INC3.0%$46.6m
MNTA MOMENTA PHARMACEUTICALS INC2.5%$38.3m
CCXIEUR CHEMOCENTRYX INC2.4%$37.2m
PRNB PRINCIPIA BIOPHARMA INC2.1%$32.8m
ESPREUR ESPERION THERAPEUTICS INC NE1.8%$28.7m
VIR VIR BIOTECHNOLOGY INC1.6%$25.4m
NBIX NEUROCRINE BIOSCIENCES INC1.4%$22.6m
8IN SYNEOS HEALTH INC1.4%$21.3m
CRSP CRISPR THERAPEUTICS AG1.3%$20.2m
MCK MCKESSON CORP1.3%$19.6m
CHRS COHERUS ONCOLOGY INC1.2%$18.3m
EDIT EDITAS MEDICINE INC1.1%$17.7m
ASND ASCENDIS PHARMA A/S1.1%$17.6m
AZN ASTRAZENECA PLC1.1%$17.2m
ALEC ALECTOR INC1.1%$16.8m
PREVAIL THERAPEUTICS INC no ticker1.0%$15.3m
RCUS ARCUS BIOSCIENCES INC0.9%$14.6m
RPRX ROYALTY PHARMA PLC0.6%$9.7m
SURFUSD SURFACE ONCOLOGY INC0.6%$9.7m
DCPHEUR DECIPHERA PHARMACEUTICALS IN0.6%$9.3m
NTLA INTELLIA THERAPEUTICS INC0.6%$8.8m
VSTM VERASTEM INC0.5%$7.6m
1LIFE HEALTHCARE INC no ticker0.5%$7.3m
AKOUOS INC no ticker0.5%$7.1m
RNAGBP AVIDITY BIOSCIENCES INC0.4%$6.6m
RTRXEUR RETROPHIN INC0.3%$5.1m
LEGN LEGEND BIOTECH CORP0.3%$4.3m
AVADEL PHARMACEUTICALS PLC no ticker0.2%$3.7m
FUSION PHARMACEUTICALS INC no ticker0.2%$2.9m
ZGNXEUR ZOGENIX INC0.2%$2.6m
PROGENITY INC no ticker0.1%$2.1m

Sector mix

  • Healthcare61.5%
  • Unclassified38.5%

Book over time

Every quarter on file (27)
QuarterPositionsEquity book
Q2 202645$624m
Q1 202645$494m
Q4 202539$347m
Q3 202543$439m
Q2 202555$499m
Q1 202563$485m
Q4 202461$1.0bn
Q3 202481$2.0bn
Q2 202485$2.4bn
Q1 202487$2.8bn
Q4 202372$2.6bn
Q3 202383$2.5bn
Q2 202393$2.9bn
Q1 202383$3.0bn
Q4 202284$4.3bn
Q3 202296$4.6bn
Q2 202282$4.4bn
Q1 202291$4.5bn
Q4 202197$4.7bn
Q3 2021103$3.9bn
Q2 2021112$3.7bn
Q1 202193$3.6bn
Q4 202094$3.0bn
Q3 202066$1.9bn
Q2 202057$1.6bn
Q1 202049$698m
Q4 201933$159m

Where Avidity Partners Management LP was early

46 rows
BTAI BIOXCEL THERAPEUTICS INCQ1 20202 of 560.7%1.3%4Exited by Q1 2021+3.4%
ALEC ALECTOR INCQ1 20205 of 872.5%2.5%2Exited by Q3 2020+1.3%
VSTM VERASTEM INCQ1 20205 of 1001.1%1.1%2Exited by Q3 2020−35%
AXSM AXSOME THERAPEUTICS INCQ1 20208 of 1411.7%2.1%17Exited by Q3 2025+77%
IDYA IDEAYA BIOSCIENCES INCQ2 20201 of 1081.2%2.9%19Exited by Q2 2025+15%
ZNTL ZENTALIS PHARMACEUTICALS INCQ2 20203 of 872.1%4.8%14Exited by Q4 2023−58%
VIR VIR BIOTECHNOLOGY INCQ2 20204 of 1141.6%1.7%11Held at last filing, Q2 2026−75%
LEGN LEGEND BIOTECH CORPQ2 20205 of 1210.3%2.6%14Held at last filing, Q2 2026−32%
NTLA INTELLIA THERAPEUTICS INCQ2 20206 of 1290.6%1.7%16Held at last filing, Q2 2026−20%
SNDX SYNDAX PHARMACEUTICALS INCQ2 20206 of 1271.5%3.5%21Exited by Q3 2025−37%
ARVN ARVINAS INCQ2 20208 of 1212.3%5.1%22Exited by Q4 2025−75%
AVTR AVANTOR INCQ2 20209 of 1841.8%6.2%17Exited by Q2 2025−4.7%
NBP I MABQ3 20202 of 663.4%3.4%5Exited by Q4 2021+54%
NTRA NATERA INCQ3 202010 of 1672.0%6.8%23Exited by Q2 2026+177%
MRVI MARAVAI LIFESCIENCES HLDGS IQ4 20201 of 1163.2%3.3%3Exited by Q3 2021+49%
ATEC ALPHATEC HLDGS INCQ4 20203 of 1020.9%1.1%10Exited by Q4 2023−11%
ORGO ORGANOGENESIS HLDGS INCQ4 20203 of 671.4%1.4%2Exited by Q2 2021+142%
SHC SOTERA HEALTH COQ4 20203 of 1320.6%1.6%5Exited by Q1 2022−14%
STTK SHATTUCK LABS INCQ4 20203 of 651.7%1.7%5Exited by Q1 2022−84%
SGRY SURGERY PARTNERS INCQ4 20205 of 1320.5%3.8%11Exited by Q1 2025−27%
IMCR IMMUNOCORE HLDGS PLCQ1 20212 of 970.7%2.1%15Exited by Q4 2024−27%
NUVB NUVATION BIO INCQ1 20213 of 972.2%2.2%6Exited by Q3 2022−69%
ACET ADICET BIO INCQ1 20217 of 720.8%1.4%5Exited by Q2 2022+53%
CGEM CULLINAN THERAPEUTICS INCQ1 20219 of 920.8%1.2%3Exited by Q4 2024−60%
BBIO BRIDGEBIO PHARMA INCQ1 202113 of 1741.4%1.4%6Held at last filing, Q2 2026+21%
CMPS COMPASS PATHWAYS PLCQ2 20214 of 1071.0%1.0%2Exited by Q4 2021−22%
DOCS DOXIMITY INCQ2 20218 of 1330.2%1.5%3Exited by Q3 2025+5.4%
STVN STEVANATO GROUP S P AQ3 20212 of 621.6%1.6%2Exited by Q1 2022−11%
CRBU CARIBOU BIOSCIENCES INCQ3 20214 of 731.5%1.5%11Exited by Q2 2024−78%
ALT ALTIMMUNE INCQ3 20218 of 1040.6%1.5%10Exited by Q3 2025−66%
KYMR KYMERA THERAPEUTICS INCQ3 20219 of 980.8%2.0%4Exited by Q1 2025−32%
RARE ULTRAGENYX PHARMACEUTICAL INQ3 20219 of 1511.0%3.2%16Exited by Q3 2025−60%
RVMD REVOLUTION MEDICINES INCQ2 20228 of 1640.6%1.9%14Exited by Q2 2026+399%
PLRX PLIANT THERAPEUTICS INCQ3 202210 of 1030.9%2.4%4Exited by Q3 2023−13%
TMDX TRANSMEDICS GROUP INCQ3 202210 of 1080.3%1.2%3Exited by Q1 2025+49%
PCVX VAXCYTE INCQ3 202213 of 1210.3%1.8%9Exited by Q2 2025+57%
BHVN BIOHAVEN LTDQ4 20229 of 1260.5%1.9%10Exited by Q2 2025+73%
ICLR ICON PLCQ4 202215 of 1611.0%1.7%4Exited by Q2 2026−43%
GPCR STRUCTURE THERAPEUTICS INCQ2 20239 of 1140.06%1.8%8Held at last filing, Q2 2026+29%
MLTX MOONLAKE IMMUNOTHERAPEUTICSQ2 202311 of 1210.7%1.8%4Exited by Q2 2026−63%
NMRA NEUMORA THERAPEUTICS INC.Q3 20233 of 751.0%1.3%5Exited by Q4 2024−6.4%
DNTH DIANTHUS THERAPEUTICS INCQ3 20235 of 970.7%35.8%12Held at last filing, Q2 2026+613%
CGON CG ONCOLOGY INCQ1 20242 of 882.3%17.7%10Held at last filing, Q2 2026+62%
JANX JANUX THERAPEUTICS INCQ1 20249 of 1090.5%4.0%5Exited by Q2 2025−28%
ORKA ORUKA THERAPEUTICS INCQ3 20247 of 831.0%11.6%8Held at last filing, Q2 2026+288%
JBIO JADE BIOSCIENCES INCQ2 20252 of 522.3%6.2%5Held at last filing, Q2 2026+122%

Concentration and tenure

6.2%
Median largest position, all quarters
The largest single position as a share of the reported equity book.
39.7%
Median top 10 weight, all quarters
The ten largest positions together, as a share of the reported equity book.
Concentrated
Style, by median largest position
2
Median completed holding, quarters